/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Avatar Integrated Systems Helps Tackle Advanced Node and Extreme Low Power Design Challenges with Aprisa 19.1 Release
Breakthrough routing and power features help designers improve
performance, capacity, low power and area concerns
SANTA CLARA, Calif.–(BUSINESS WIRE)–Avatar Integrated Systems, a leader in next-generation physical design
solutions, today announced it has added major new features to its
Aprisa place & route solution. Avatar introduced Sibling Routing and
PowerFirst technologies in the upcoming Aprisa 19.1 release, two
technologies designed to address the performance and capacity challenges
of place and route at advanced process nodes, and the demands for
extreme low power and smaller silicon area at mainstream nodes.
This latest innovation demonstrates Avatar’s dedication to helping
designers overcome some of the most daunting challenges in integrated
circuit design today. For example, there’s increased design complexity
as well as ceaseless demand for faster computation speed in applications
such as cloud computing, AI, ML, mobile, 5G, and other areas. This has
spurred many companies to more quickly adopt advanced process nodes with
more complex technology constraints and new design challenges.
On the other hand, emerging application areas such as Internet-of-Things
(IoT), edge computing, and battery-powered devices, require extremely
low stand-by and active mode power consumption.
“The 19.1 release is an evidence of our continuous technology innovation
in digital place and route,” said Ping-San Tzeng, CTO of Avatar
Integrated Systems. “We are confident that the 7FF certification,
Sibling Routing, and PowerFirst technology will greatly help our user to
achieve their design successes.”
The Aprisa 19.1 release includes many features that dramatically improve
the runtime, capacity, design convergence, and the final quality of
results (performance, power, area) of the designs. In particular, the
new release introduces the following unique technologies:
-
Release 19.1 includes support for TSMC 7FF technology node.
Avatar collaborated with TSMC to complete rigorous
certification tasks to ensure full support of the 7nm FF node in
the area of design enablement, reference flow, correlation with
signoff, and quality-of-results. All 7FF design collaterals are now
available for immediate design start. -
Sibling Routing technology. At advanced process nodes, such as
7nm, the impact of high resistivity of wires and vias at lower metal
layers can cause timing and electromigration (EM) issues. Avatar’s
patented Sibling Routing is an innovative technology that addresses
those issues. Sibling Routing uses multiple wires and vias to connect
a single net at lower layers, rather than single wire and single via,
which is found in traditional routers. The new routing model provides
lower net resistivity, which results in improved timing, higher clock
speed, and better routability and EM reliability. -
Release 19.1 also introduces PowerFirst technology for
extreme low-power design at any node. In traditional design
techniques, conventional place-and-route algorithms tend to focus on
maximizing design performance (timing), while minimize power and area
as much as possible. This approach often leads to over-design for
timing, while leaving much power saving on the table. Avatar’s
PowerFirst technology puts power front-and-center of the design
target. It optimizes the designs for the lowest power first, then
makes necessary tradeoff to meet timing. The technology includes a
suite of features spanning the entire design flow, covering both
standby power and active-mode power. It is the optimal place-and-route
technology for today’s power-sensitive designs.
Visit Avatar in Booth #967 at the upcoming Design
Automation Conference (DAC) to learn more about Aprisa’s Sibling
Routing technology and PowerFirst. Sign up today for a private
demo with Avatar at DAC. The 56th DAC will be held in the
Las Vegas Convention Center in Las Vegas, Nevada from Sunday, June 2 to
Thursday, June 6.
About Avatar Integrated Systems
Avatar Integrated Systems is a leading software company in the
Electronic Design Automation (EDA) industry focused on Physical Design
Implementation. The company’s products enable integrated circuit (IC)
designers to create semiconductor chips, which enable today’s electronic
devices, such as smartphones, computers, internet equipment, IoT
wearables, etc. Avatar’s products are built on the proven technologies
acquired from ATopTech, Inc. Avatar Integrated Systems is headquartered
in Santa Clara, Calif. with subsidiaries and offices in Taiwan, India,
Japan, and Korea. The company continues to serve global customers with
cutting-edge digital place-and-route technology and closely partners
with customers to reach their design successes. For more information
visit: www.avatar-da.com.
Contacts
Michelle Clancy
Cayenne Communication
503 702 4732
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
transfer
IMC to transfer its Oranim Pharmacy shares back to the seller
TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the seller.
“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, the occurrence of growth opportunities and the likelihood of growth potential.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East
Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.
The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contacts:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html
Cannabis
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Avant2 weeks ago
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt2 weeks ago
StickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services